Association between statewide financial incentive programs and COVID-19 vaccination rates.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 18 10 2021
accepted: 18 01 2022
entrez: 30 3 2022
pubmed: 31 3 2022
medline: 15 4 2022
Statut: epublish

Résumé

To promote COVID-19 vaccination, many states in the US introduced financial incentives ranging from small, guaranteed rewards to lotteries that give vaccinated individuals a chance to win large prizes. There is limited evidence on the effectiveness of these programs and conflicting evidence from survey experiments and studies of individual states' lotteries. To assess the effectiveness of COVID-19 vaccination incentive programs, we combined information on statewide incentive programs in the US with data on daily vaccine doses administered in each state. Leveraging variation across states in the daily availability of incentives, our difference-in-differences analyses showed that statewide programs were not associated with a significant change in vaccination rates. Furthermore, there was no significant difference in vaccination trends between states with and without incentives in any of the 14 days before or after incentives were introduced. Heterogeneity analyses indicated that neither lotteries nor guaranteed rewards were associated with significant change in vaccination rates.

Identifiants

pubmed: 35353815
doi: 10.1371/journal.pone.0263425
pii: PONE-D-21-32893
pmc: PMC8966995
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0263425

Déclaration de conflit d'intérêts

Dr. Volpp is a co-owner of VAL Health. No other disclosures are reported. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

JAMA. 2021 Aug 24;326(8):766-767
pubmed: 34213530
Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24144-24153
pubmed: 32934147
PLoS One. 2014 Mar 11;9(3):e90347
pubmed: 24618584
Proc Natl Acad Sci U S A. 2021 Aug 10;118(32):
pubmed: 34312254
Econ Lett. 2021 Dec;209:110097
pubmed: 35153345
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):
pubmed: 34413212
J Health Econ. 2022 Jan;81:102578
pubmed: 34986437

Auteurs

Harsha Thirumurthy (H)

Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.

Katherine L Milkman (KL)

Department of Operations, Information and Decisions, The Wharton School, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.

Kevin G Volpp (KG)

Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.

Alison M Buttenheim (AM)

Department of Family and Community Health, School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.

Devin G Pope (DG)

Booth School of Business, University of Chicago, Chicago, Illinois, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH